Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.72, $0.07 better than the analyst estimate of $0.65. Revenue for the quarter came in at $127.7 million versus the consensus estimate of $130.38 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.